TCM
ALXN

Tributary Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tributary Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,000
Closed -$2.76M – 239
2021
Q2 		$2.76M Sell
15,000
-200
-1% -$34.3K 0.21% 79
2021
Q1 		$2.32M Hold
15,200
– – 0.18% 88
2020
Q4 		$2.38M Hold
15,200
– – 0.17% 87
2020
Q3 		$1.74M Buy
+15,200
New +$1.64M 0.15% 113

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tributary Capital Management's ALXN Position: Q3 2021 in Review

Tributary Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 15,000 shares — an estimated $2.76M sold.

Tributary Capital Management first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $2.76M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Tributary Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tributary Capital Management sold 15,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.76M.
  • Tributary Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Tributary Capital Management's Alexion Pharmaceuticals position peaked at $2.76M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tributary Capital Management's 13F filing for Q3 2021, filed 14 Oct 2021.